832 related articles for article (PubMed ID: 19481373)
1. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
[TBL] [Abstract][Full Text] [Related]
2. Anti-HER2 vaccines: new prospects for breast cancer therapy.
Ladjemi MZ; Jacot W; Chardès T; Pèlegrin A; Navarro-Teulon I
Cancer Immunol Immunother; 2010 Sep; 59(9):1295-312. PubMed ID: 20532501
[TBL] [Abstract][Full Text] [Related]
3. Immunizing against breast cancer: a new swing for an old sword.
Curigliano G; Locatelli M; Fumagalli L; Goldhirsch A
Breast; 2009 Oct; 18 Suppl 3():S51-4. PubMed ID: 19914543
[TBL] [Abstract][Full Text] [Related]
4. Cancer vaccines: an update.
Hipp JD; Hipp JA; Lyday BW; Minev BR
In Vivo; 2000; 14(5):571-85. PubMed ID: 11125541
[TBL] [Abstract][Full Text] [Related]
5. Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines.
Benavides LC; Sears AK; Gates JD; Clifton GT; Clive KS; Carmichael MG; Holmes JP; Mittendorf EA; Ponniah S; Peoples GE
Expert Rev Vaccines; 2011 Feb; 10(2):201-10. PubMed ID: 21332269
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells pulsed with an anti-idiotype antibody mimicking Her-2/neu induced protective antitumor immunity in two lines of Her-2/neu transgenic mice.
Saha A; Chatterjee SK
Cell Immunol; 2010; 263(1):9-21. PubMed ID: 20236626
[TBL] [Abstract][Full Text] [Related]
7. HER-2/neu as a target for cancer vaccines.
Baxevanis CN; Voutsas IF; Gritzapis AD; Perez SA; Papamichail M
Immunotherapy; 2010 Mar; 2(2):213-26. PubMed ID: 20635929
[TBL] [Abstract][Full Text] [Related]
8. Antitumor vaccination: where we stand.
Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S
Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658
[TBL] [Abstract][Full Text] [Related]
9. Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines.
Wiedermann U; Davis AB; Zielinski CC
Breast Cancer Res Treat; 2013 Feb; 138(1):1-12. PubMed ID: 23340862
[TBL] [Abstract][Full Text] [Related]
10. Enhanced immunity by NeuEDhsp70 DNA vaccine Is needed to combat an aggressive spontaneous metastatic breast cancer.
Kim JH; Majumder N; Lin H; Chen J; Falo LD; You Z
Mol Ther; 2005 Jun; 11(6):941-9. PubMed ID: 15922965
[TBL] [Abstract][Full Text] [Related]
11. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.
Park JW; Melisko ME; Esserman LJ; Jones LA; Wollan JB; Sims R
J Clin Oncol; 2007 Aug; 25(24):3680-7. PubMed ID: 17704416
[TBL] [Abstract][Full Text] [Related]
12. DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice.
Cao J; Jin Y; Li W; Zhang B; He Y; Liu H; Xia N; Wei H; Yan J
BMC Immunol; 2013 Aug; 14():39. PubMed ID: 23941509
[TBL] [Abstract][Full Text] [Related]
13. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
14. Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase.
Montgomery RB; Makary E; Schiffman K; Goodell V; Disis ML
Cancer Res; 2005 Jan; 65(2):650-6. PubMed ID: 15695410
[TBL] [Abstract][Full Text] [Related]
15. Cancer vaccines: an update with special focus on ganglioside antigens.
Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu.
Mohanty K; Saha A; Pal S; Mallick P; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
Breast Cancer Res Treat; 2007 Jul; 104(1):1-11. PubMed ID: 17004107
[TBL] [Abstract][Full Text] [Related]
17. Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine.
Knutson KL; Disis ML
Clin Breast Cancer; 2001 Apr; 2(1):73-9. PubMed ID: 11899386
[TBL] [Abstract][Full Text] [Related]
18. Antibodies and vaccines--hope or illusion?
Jäger D; Knuth A
Breast; 2005 Dec; 14(6):631-5. PubMed ID: 16242931
[TBL] [Abstract][Full Text] [Related]
19. Immunology and breast cancer: therapeutic cancer vaccines.
Curigliano G; Rescigno M; Goldhirsch A
Breast; 2007 Dec; 16 Suppl 2():S20-6. PubMed ID: 17706425
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial.
Mittendorf EA; Storrer CE; Foley RJ; Harris K; Jama Y; Shriver CD; Ponniah S; Peoples GE
Cancer; 2006 Jun; 106(11):2309-17. PubMed ID: 16596621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
